Cell MedX Corp. (CMXC)
USD 0.43
(N/A%)
USD 0.43
(N/A%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | - USD | 100.0% |
| 2023 | -447.65 Thousand USD | 33.24% |
| 2022 | -670.54 Thousand USD | -38.56% |
| 2021 | -721.91 Thousand USD | 53.31% |
| 2020 | -1.03 Million USD | -16.63% |
| 2019 | -669.62 Thousand USD | 42.13% |
| 2018 | -1.38 Million USD | -39.94% |
| 2017 | -1.07 Million USD | 47.34% |
| 2016 | -2.08 Million USD | -121.36% |
| 2015 | -1 Million USD | -4980.75% |
| 2014 | -18.52 Thousand USD | -46.62% |
| 2013 | -12.63 Thousand USD | 20.32% |
| 2012 | -15.85 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - USD | 40.05% |
| 2024 Q1 | -51.05 Thousand USD | 21.18% |
| 2024 Q2 | -42.56 Thousand USD | 16.63% |
| 2024 Q3 | -57.77 Thousand USD | -35.74% |
| 2024 Q4 | -116.96 Thousand USD | -102.44% |
| 2023 Q1 | -145 Thousand USD | 5.78% |
| 2023 FY | - USD | 33.24% |
| 2023 Q2 | -132.04 Thousand USD | 8.93% |
| 2023 Q3 | -105.83 Thousand USD | 19.85% |
| 2023 Q4 | -64.77 Thousand USD | 38.8% |
| 2022 Q1 | -233.87 Thousand USD | -487.36% |
| 2022 FY | - USD | -38.56% |
| 2022 Q4 | -153.9 Thousand USD | -36.87% |
| 2022 Q2 | -170.33 Thousand USD | 27.17% |
| 2022 Q3 | -112.44 Thousand USD | 33.99% |
| 2021 Q4 | 60.37 Thousand USD | 135.63% |
| 2021 Q1 | -194.02 Thousand USD | 21.0% |
| 2021 Q2 | -180.82 Thousand USD | 6.8% |
| 2021 FY | - USD | 53.31% |
| 2021 Q3 | -169.45 Thousand USD | 6.29% |
| 2020 Q2 | -299.16 Thousand USD | -25.66% |
| 2020 Q4 | -245.58 Thousand USD | 3.2% |
| 2020 Q1 | -238.06 Thousand USD | -73.5% |
| 2020 FY | - USD | -16.63% |
| 2020 Q3 | -253.69 Thousand USD | 15.2% |
| 2019 FY | - USD | 42.13% |
| 2019 Q4 | -137.21 Thousand USD | 64.4% |
| 2019 Q3 | -385.38 Thousand USD | -208.9% |
| 2019 Q2 | -124.75 Thousand USD | 48.3% |
| 2019 Q1 | -241.32 Thousand USD | 31.0% |
| 2018 Q1 | -786.23 Thousand USD | -115.31% |
| 2018 Q2 | -142.62 Thousand USD | 81.86% |
| 2018 FY | - USD | -39.94% |
| 2018 Q3 | -256.97 Thousand USD | -80.17% |
| 2018 Q4 | -349.73 Thousand USD | -36.1% |
| 2017 Q4 | -365.16 Thousand USD | -35.34% |
| 2017 Q1 | -239.15 Thousand USD | 15.36% |
| 2017 FY | - USD | 47.34% |
| 2017 Q3 | -269.82 Thousand USD | -20.9% |
| 2017 Q2 | -223.16 Thousand USD | 6.68% |
| 2016 Q3 | -292.59 Thousand USD | 38.66% |
| 2016 FY | - USD | -121.36% |
| 2016 Q4 | -282.55 Thousand USD | 3.43% |
| 2016 Q2 | -477.02 Thousand USD | 53.75% |
| 2016 Q1 | -1.03 Million USD | -252.78% |
| 2015 Q4 | -292.38 Thousand USD | 23.62% |
| 2015 FY | - USD | -4980.75% |
| 2015 Q3 | -382.79 Thousand USD | -40.08% |
| 2015 Q2 | -273.27 Thousand USD | -470.25% |
| 2015 Q1 | -47.92 Thousand USD | -788.93% |
| 2014 FY | - USD | -46.62% |
| 2014 Q1 | -5927.00 USD | -295.13% |
| 2014 Q4 | -5391.00 USD | -23.36% |
| 2014 Q2 | -2839.00 USD | 52.1% |
| 2014 Q3 | -4370.00 USD | -53.93% |
| 2013 Q4 | -1500.00 USD | 76.31% |
| 2013 Q2 | -4805.00 USD | 0.0% |
| 2013 FY | - USD | 20.32% |
| 2013 Q1 | - USD | 100.0% |
| 2013 Q3 | -6331.00 USD | -31.76% |
| 2012 Q2 | -5882.00 USD | 37.12% |
| 2012 Q3 | -4109.00 USD | 30.14% |
| 2012 Q4 | -2293.00 USD | 44.2% |
| 2012 Q1 | -9354.00 USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| RetinalGenix Technologies Inc. | -2.08 Million USD | 100.0% |